LINGO-1 Regulates Oligodendrocyte Differentiation through the Cytoplasmic Gelsolin Signaling Pathway
Zhaohui Shao(Biogen (United States)), Sha Mi(Biogen (United States))
Cited by 42
Related Papers
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
|The Lancet Neurology|2019|185
Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies
|Neurology Neuroimmunology & Neuroinflammation|2017|30